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Abstract:   31 
There is an ever-increasing recognition that bile acids are not purely simple surfactant 32 
molecules that aid in lipid digestion, but are a family of molecules contributing to a diverse 33 
range of key systemic functions in the host.  It is now also understood that the specific 34 
composition of the bile acid milieu within the host is related to the expression and activity of 35 
bacterially-derived enzymes within the gastrointestinal tract, as such creating a direct link 36 
between the physiology of the host and the gut microbiota.  Coupled to the knowledge that 37 
perturbation of the structure and/or function of the gut microbiota may contribute to the 38 
pathogenesis of a range of diseases, there is a high level of interest in the potential for 39 
manipulation of the gut microbiota-host bile acid axis as a novel approach to therapeutics.  40 
Much of the growing understanding of the biology of this area reflects the recent 41 
development and refinement of a range of novel techniques; this study applies a number of 42 
those techniques to the analysis of human samples, aiming to illustrate their strengths, 43 
drawbacks and biological significance at all stages.  Specifically, we used microbial profiling 44 
(using 16S rRNA gene sequencing), bile acid profiling (using liquid chromatography-mass 45 
spectrometry), bsh and baiCD qPCR, and a BSH enzyme activity assay to demonstrate 46 
differences in the gut microbiota and bile metabolism in stool samples from healthy and 47 
antibiotic-exposed individuals.     48 
 49 
1. Introduction: 50 
1.1. Overview: 51 
The last few years have been associated with a rapid increase in understanding of the 52 
profound contribution of the gut microbiota to the health of the host, as well as its potential 53 
roles in the onset and maintenance of a range of diseases.  Much initial interest in the gut 54 
microbiota has focused on observational studies which defined changes to the structure of 55 
the microbiota in different scenarios (e.g. different disease states, impact of diet or 56 
antibiotics, etc).  However, more recent emphasis has moved away from solely defining the 57 
structure of the microbiota, but refocused upon better defining its function, and specifically 58 
the many complex routes of communication (including metabolic pathways, immune axes, 59 
etc) between the gut microbiota and the host [1].  Given that a key regulator of the 60 
composition of the bile acid pool within mammals is the action of bacterially-derived enzymes 61 
within the gastrointestinal tract [2], an improved understanding of the close interplay 62 
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between the gut microbiota and the host’s ďile aĐid ŵetaďolisŵ is aŶ area of partiĐular 63 
interest.   64 
 65 
1.2. Gut microbiota-bile acid interactions in vivo: 66 
Primary bile acids (BA) are synthesised from cholesterol in the liver, where they are 67 
conjugated with glycine or taurine.  These conjugated bile acids subsequently enter the 68 
gallbladder, and are released into the duodenum following the intake of food.  Once in the 69 
small bowel, the bile acids undertake one of their key physiological roles, the emulsification 70 
and solubilisation of dietary lipids.  Bile acids will continue along the small intestine, towards 71 
the terminal ileum; whilst approximately 95% of bile acids will be reabsorbed via the 72 
enterohepatic circulation pathway, the remaining 5% (~400-800 mg per day) are not 73 
recovered, and will continue through the distal gut of the terminal ileum and on to the colon 74 
[3]. 75 
 76 
It is within the small intestine that bile acid modification by the gut microbiota is initiated, 77 
driven by enzymes that are produced and secreted by gut microbiota members, but which 78 
are not produced by the mammalian host.  The first stage of bile acid modification by the gut 79 
microbiota is from the enzymes named bile salt hydrolases (BSHs).  These enzymes 80 
deconjugate the taurine and glycine groups from conjugated bile acids via a hydrolysis 81 
reaction, and therefore reform the primary bile acids cholate (CA) and chenodeoxycholate 82 
(CDCA).  BSHs are found mainly within the bacterial phyla Firmicutes and Bacteroidetes, but 83 
are widely-distributed throughout most major bacterial divisions and archaeal species of the 84 
human gut microbiota [4].  At least eight different bsh genes exist (see Supplementary Figure 85 
1), with each form having specific properties relating to optimal pH, specificity for taurine- or 86 
glycine-conjugated bile acids and gene size [4].  The secondary enzymatic steps are 7--87 
dehydroxylation.  In these steps, the hydroxyl group of C-7 is removed, thus converting 88 
primary bile acids to secondary bile acids.  Specifically, in humans, this includes the conversion 89 
of cholate to deoxycholate (DCA), and the conversion of chenodeoxycholate to lithocholate 90 
(LCA), along with the biosynthesis of other secondary bile acids.  7--dehydroxylation is a 91 
complex, multi-step process, and only performed by strictly anaerobic bacteria with the bile 92 
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acid-inducible (bai) operon.  Based on current microbial genomic annotation, it is estimated 93 
that only a very small percentage of gut microbiota members possess 7--dehydroxylation 94 
activity, with those organisms that do predominantly belonging to the genera Clostridium 95 
clusters XIVa and XI [5], [6].  Generation of secondary bile acids creates a more hydrophobic 96 
bile acid pool, facilitating the elimination of these bile acids within faeces.  A range of other 97 
gut microbial metabolic actions against bile acids are also described, including the 98 
epimerisation of CDCA to synthesise ursodeoxycholic acid, as well as other pathways that 99 
result in the generation of iso-, allo- and oxo-/keto-bile acids [2].    100 
 101 
There is now increasing recognition of the diverse roles of bile acids within the host, in 102 
particular via their role as endogenous ligands for host cell receptors.  These include the 103 
nuclear receptor farnesoid X receptor (FXR), and the G protein-coupled plasma membrane 104 
bile acid receptor TGR5, all exhibiting varying affinities for different bile acids and their 105 
moieties [2].  Bile acids as FXR and TGR5 agonists contribute to a wealth of host physiological 106 
processes including the modulation of lipid, glucose and energy homeostasis, as well as the 107 
regulation of bile acid synthesis, conjugation and transport.  To add to the complexity, there 108 
is also evidence that bile acids influence microbiota composition, both via direct and indirect 109 
actions [2].  Collectively, the growing evidence for the multiple functions of bile acids within 110 
the host – coupled with evidence demonstrating the complex interplay between bile acid 111 
metabolism and the gut microbiota – highlights that this axis is a key mechanism by which the 112 
gut microbiota directly influences a range of aspects of host physiology.   113 
 114 
Two of the most important questions iŶ gut ŵiĐroďioŵe researĐh are ͞ǁho is there?͟ aŶd 115 
͞ǁhat are they doiŶg?͟.  IŶ the ĐoŶteǆt of ďile ŵetaďolisŵ ǁe ĐaŶ desĐriďe ĐhaŶges iŶ the gut 116 
microbiota at several different levels: we can use microbial DNA to define the composition of 117 
the gut microbiota and quantify the amount of bile metabolising genes, we can look at the 118 
amount of bile metabolising proteins expressed by measuring their enzymatic activity, and 119 
we can look at the metabolites being produced by characterising the quantity and 120 
composition of bile acid metabolites.  In this study we use a set of stool samples from 121 
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individuals exposed to antibiotics and non-antibiotic-exposed controls to demonstrate how 122 
researchers can apply a wide variety of techniques to more fully characterise microbiota-bile 123 
interactions in the gut.  These techniques include 16S rRNA gene sequencing, liquid 124 
chromatography-mass spectrometry-based bile acid profiling, BSH and 7-a-dehydroxylase 125 
qPCR, and a BSH enzyme activity assay.  In addition, we correlated metataxonomic and 126 
metabonomic data to gain a better understanding of the modulation of the bile acid pool by 127 
the gut microbiota.   128 
 129 
2. Material and methods: 130 
2.1. Study participants: 131 
The study was performed under approval from the UK National Research Ethics Centre 132 
(13/LO/1867).  Stool samples were collected from a total of eight healthy individuals, and five 133 
patients who had recently taken recurrent courses of antibiotics.  Antibiotics had been 134 
prescribed for a variety of indications, had been used for at least three continuous weeks 135 
within the past month, and had last been used between 3 – 6 days prior to sample collection 136 
(Supplementary Table 1).  Healthy individuals had not used antibiotics or been prescribed 137 
regular medications for at least six months prior to sample collection.  Stool specimens were 138 
put on ice within 15 minutes after collection, transferred to the hospital laboratory, and 139 
homogenised and aliquoted within 30 minutes.  Samples were frozen to and maintained at -140 
80oC prior to analysis. 141 
 142 
2.2. DNA extraction and 16S rRNA gene sequencing: 143 
DNA was extracted from 250 mg of stool using the PowerLyzer PowerSoil DNA Isolation Kit 144 
;Mo Bio, Carlsďad, CA, U“AͿ folloǁiŶg ŵaŶufaĐturer’s iŶstruĐtioŶs, ǁith the additioŶ of a ďead 145 
beating step for 3 minutes at speed 8 in a Bullet Blender Storm (Chembio Ltd, St Albans, UK). 146 
DNA was stored at -80°C until it was ready to be used. 147 
 148 
“aŵple liďraries ǁere prepared folloǁiŶg IlluŵiŶa’s 16“ MetageŶoŵiĐ “eƋueŶĐiŶg Liďrary 149 
Preparation Protocol [7] with two modifications. Firstly, the V1-V2 regions of the 16S rRNA 150 
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gene were amplified using the primers listed in Table 1.  Additionally, the index PCR reactions 151 
were cleaned up and normalised using the SequalPrep Normalization Plate Kit (Life 152 
Technologies, Paisley, UK). Sample libraries were quantified using the NEBNext Library Quant 153 
Kit for Illumina (New England Biolabs, Hitchin, UK).  Sequencing was performed on an Illumina 154 
MiSeq platform (Illumina Inc., Saffron Walden, UK) using the MiSeq Reagent Kit v3 (Illumina) 155 
and paired-end 300bp chemistry.  156 
 157 
The resulting data was analysed using the Mothur package following the MiSeq SOP Pipeline 158 
[8].  The Silva bacterial database was used for sequence alignments (www.arb-silva.de/) and 159 
the RDP database reference sequence files were used for classification of sequences using the 160 
Wang method [9].  The non-metric multidimensional scaling (NMDS) plot and PERMANOVA 161 
p-values were generated using the UniFrac weighted distance matrix generated from Mothur, 162 
and analysed using the Vegan library within the R statistical package [10].  Family-level 163 
extended error bar plots were generated using the Statistical Analysis of Metagenomic 164 
Profiles softǁare paĐkage usiŶg White’s ŶoŶ-parametric t-test with Benjamini-Hochberg FDR 165 
[11].  The α diversity ;“haŶŶoŶ diversity iŶdeǆ, H’Ϳ aŶd riĐhŶess ;total Ŷuŵďer of ďaĐterial taǆa 166 
observed, Sobs) were calculated within Mothur and statistical tests (independent t-test and 167 
Mann-Whitney U test, respectively) were performed using IBM SPSS Statistics Software 168 
version 23. A p-value of 0.05 and a q-value of 0.05 was considered significant. 169 
 170 
2.3. Inference of gut microbiota function from 16S rRNA gene sequencing data: 171 
To predict the bile-metabolising ability of the microbial communities within the samples, an 172 
inferential tool, Piphillin, was applied [12].  This algorithm uses direct nearest-neighbour 173 
matching between 16S rRNA gene sequencing datasets and microbial genomic databases to 174 
infer the metagenomic content of the samples [12].  In this case, Piphillin was used online 175 
[13], using the KEGG May 2017 as reference database, and applying 97% identity cut-off.  176 
Inference of gene abundance was assessed for KEGG orthology K01442 (cholylglycine 177 
hydrolase, an alternative name for BSH), KEGG orthology K15870 (baiCD, a bacterial gene 178 
specific to the 7--dehydroxylation pathway) and KEGG pathway ko00121 (corresponding to 179 
the secondary bile acid biosynthesis pathway).   180 
 181 
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2.4. Ultra performance liquid chromatography-mass spectrometry (UPLC-MS) profiling 182 
of faecal bile acids: 183 
Faecal samples were lyophilized for 24 hours using a VirTis Benchtop BTP 8ZL freeze dryer 184 
(BPS, UK).  The dried samples were weighed and bile acids were extracted using a 2:1:1 (vol) 185 
mixture of water, acetonitrile and 2-propanol in a Biospec bead beater with 1.0 mm Zirconia 186 
beads.  After centrifugation (16,000 x g, 20 minutes) the supernatant was filtered using 0.45 187 
μŵ microcentrifuge filters (Costar, Corning).  188 
 189 
Quality control (QC) samples were prepared using equal parts of the faecal filtrates. QC 190 
samples were used as an assay performance monitor[14], and as a proxy to remove features 191 
with high variation. QC samples were also spiked with mixtures of bile acid standards (55 bile 192 
acid standards including 36 non-conjugated, 12 conjugated with taurine, seven conjugated 193 
with glycine (Steraloids, Newport, RI, USA)) and were analysed along with the stool samples 194 
to determine the chromatographic retention times of bile acids and to aid in metabolite 195 
identification.  196 
 197 
Bile acid analysis of faecal extracts was performed using ACQUITY UPLC (Waters Ltd, Elstree, 198 
UK) coupled to a Xevo G2 Q-ToF mass spectrometer equipped with an electrospray ionization 199 
source operating in negative ion mode (ESI-), using the method described by Sarafian and 200 
colleagues [15].  201 
 202 
Waters raw data files were converted to NetCDF format and data were extracted using XCMS 203 
(v1.50) package with R (v3.1.1) software.  Probabilistic quotient normalisation [16] was used 204 
to correct for dilution effects and chromatographic features with coefficient of variation 205 
higher than 30% in the QC samples were excluded from further analysis. 206 
 207 
The relative intensities of the features were corrected to the dry weight of the faecal samples. 208 
 209 
2.5. Integration of 16S rRNA gene sequencing data and bile acid mass spectrometry data: 210 
CorrelatioŶs ďetǁeeŶ tǁo ͞oŵiĐ͟ datasets aĐƋuired froŵ the saŵe set of saŵples ǁere 211 
determined using regularised Canonical Correlation Analaysis (rCCA).  rCCA modelling of 212 
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metataxonomic (16S rRNA gene sequencing) and metabonomic (bile acid mass spectrometry) 213 
data was employed in the mixOmics library within the R statistical package [17], [18].  The 214 
regularisation parameters were determined using the shrinkage method. The rCCA similarity 215 
scores between the variables were plotted as heatmaps using the clustered image maps (cim) 216 
function. Hierarchical clustering (complete linkage, Euclidean distance) was used to obtain 217 
the order of the variables. The correlation circle plot was generated using the plotVar 218 
function, which plots strong correlations between variables (plots variables with a correlation 219 
above 0.5 outside of the inner circle). 220 
 221 
2.6. Abundance and activity of bile-metabolising enzymes: 222 
2.6.1. Real-time PCR for the quantification of BSH and baiCD gene abundance: 223 
qPCR was performed using extracted DNA to quantify gene abundance.  Gene abundance was 224 
quantified for i) specified groups of bsh (using degenerate primer sets previously designed 225 
and optimised by our group (Table 2)) and ii) baiCD (using primers previously described in the 226 
literature [19]).  227 
 228 
A total reaction volume of 25µl was used for each reaction, consisting of 20µl master mix and 229 
5µl diluted DNA (12.5ng total per reaction). All DNA was diluted in buffer EB (Qiagen, Hilden, 230 
Germany). A standard master mix consisting of 5.5µl PCR grade water (Roche, Penzberg, 231 
Germany), 12.5µl of 2x SYBR green master mix (ThermoFisher Scientific, Waltham, 232 
Massachusetts, USA), 1µl of 10µM forward primer (Eurofins Genomics, Wolverhampton, UK) 233 
and 1µl of 10µM reverse primer (Eurofins Genomics) was used.  One bacterial strain from the 234 
relevant reference group was selected as a standard for each primer set (bsh group 1a – 235 
Bacteroides plebius; bsh group 1b – Bacteroides ovatus; bsh group 3c/e – Blautia obeum; 236 
baiCD – Clostridium scindens (DSMZ 5676, Braunschweig, Germany) (Supplementary 237 
Methods).  Serial dilutions of each isolate were used to create a standard curve. 238 
Thermocycling conditions for each primer set are summarised in Table 2.  A melt curve stage 239 
was performed post-cycling to confirm primer specificity. Products were also visualised using 240 
the 2200 Tapestation System (Aligent Technologies, Santa Clara, California, USA) in 241 
combination with D1000 Reagents and D100 Screentapes (Aligent Technologies), following 242 
the ŵaŶufaĐturer’s protoĐol.  243 
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 244 
Copy number was calculated from qPCR data using the following formula: gene abundance = 245 
(quantity (ng) x 6.022 x 1023 (gene copy number/mol)) / (length of product x 1 x 109 (ng/g) x 246 
660 (g/mol)).  A mean copy number for each set of triplicates was calculated and divided by 247 
the total DNA per reaction to obtain average copy number per ng DNA. 248 
 249 
2.6.2. Bile salt hydrolase enzyme activity assay: 250 
Faecal water was prepared and total faecal protein quantified using a similar method to that 251 
previously-described by Morris and Marchesi [20], but with the addition of bacterial and 252 
mammalian protease inhibitor cocktails (G Biosciences, St Louis, MO, USA), as well as DTT to 253 
1mM final concentration (Roche, Welwyn Garden City, UK) to minimise enzyme oxidation 254 
[21].   255 
 256 
The BSH assay itself was an adaptation of a precipitation-based assay [21]–[23].  The assay 257 
was performed in a clear flat-bottomed 96-well microtitre plate and incubated at 37oC at pH 258 
5.8 for up to 8 hours.  In a total volume of 200l, 500g of faecal protein was incubated with 259 
sodium phosphate buffer (pH 5.8, final concentration of 0.02mM), and taurodeoxycholic acid 260 
(Merck, Damstadt, Germany) (at final concentration 1mM).  To prevent evaporation during 261 
incubation, wells were overlaid with 50l of light paraffin oil (0.85g/ml; PanReac AppliChem, 262 
Barcelona, Spain) [23].  Samples were assayed in triplicate, with precipitation of insoluble 263 
deoxycholic acid monitored by absorbance measurement at 600nm (A600) using a microplate 264 
reader (MultiSkan Go, Thermo Scientific, Dartford, UK).  Faecal protein incubated with 265 
phosphate-buffered saline served as a negative control, and faecal protein incubated with 266 
varying concentrations of deoxycholic acid (Merck) was used to establish a standard curve to 267 
quantify precipitate formation.   268 
 269 
2.6.3.  Statistical analysis: 270 
A Mann-Whitney U test was used to compare the BSH activity and the BSH and baiCD gene 271 
abundance data between the antibiotic treated and healthy cohorts.  A p-value of <0.05 was 272 
considered significant. 273 
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 274 
3. Results: 275 
3.1. 16S rRNA gene sequencing: 276 
16S rRNA gene sequencing analysis showed patients taking recurrent antibiotics had altered 277 
compositions of their gut microbiotas compared to healthy controls (Figure 1A, p < 0.01, 278 
PERMANOVA).  Patients taking recurrent antibiotics had lower microbial community diversity 279 
(Figure 1B, p < 0.001, independent t-test) and richness (Figure 1C, p < 0.01, Mann-Whitney U 280 
test) compared to healthy controls.  Statistical analysis showed that the altered microbiota in 281 
patients taking recurrent antibiotics were due to decreases in the relative abundances of the 282 
families Bacteroidaceae, Lachnospiraceae, Ruminococcaceae, and Oscillospiraceae, and 283 
increases in the relative abundance of the family Enterobacteriaceae compared to healthy 284 
controls (Figure 1D). 285 
 286 
3.2. Inference of gut microbiota function from 16S rRNA gene sequencing data: 287 
Results from Piphillin analysis are shown in Figure 2.  Predicted gene abundance for bsh (KEGG 288 
orthologue K01442) was significantly reduced in patients who had taken recurrent antibiotics 289 
(Figure 2A, p < 0.05, Mann-Whitney U test).  It was not possible to predict gene abundance 290 
counts for all samples for baiCD (KEGG orthologue K15870) at the cut-off of 97% identity used, 291 
implying very low counts.  Predicted secondary bile acid biosynthesis (ko00121) trended 292 
lower in patients with recurrent antibiotic use compared to controls, but this was not 293 
significant (Figure 2B, p = 0.08).   294 
 295 
3.3. Multivariate statistics analysis of UPLC-MS profiling data: 296 
The data table produced by XCMS after normalization to the dry weight of the samples was 297 
introduced to SIMCA 14.1 (MKS Umetrics AB).  Principal component analysis (PCA) was 298 
performed to visualise clustering of samples and assess the quality of the run using the QC 299 
samples (Figure 3A).  Furthermore, supervised OPLS-DA was performed (Figure 3B) to reveal 300 
the features that were responsible for the discrimination between the recurrent antibiotic-301 
treated and healthy control groups.  This feature identification was achieved using the S-plot 302 
presented in Figure 3C, where feature in the edges of the S-shaped cloud of features were 303 
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responsible for the separation.  Features on top right were higher in the healthy control 304 
group, and in bottom left higher in the group treated with recurrent antibiotics.  Annotated 305 
bile acids are highlighted in the plot. 306 
 307 
Univariate analysis for differences in specific bile acids between healthy participants and 308 
people treated with recurrent antibiotics was also performed; data are presented in 309 
Supplementary Figure 2.   310 
 311 
3.4. Integration of metataxonomic and metabonomic data: 312 
rCCA modelling was used to determine correlations between metataxonomic (16S rRNA gene 313 
sequencing) and metabonomic (bile acid mass spectrometry) data (Figure 4).  We found that 314 
correlations between bacterial families and bile acids clustered into three distinct groups 315 
(Figure 4). Group 1 consisted of correlations where bacterial families were positively 316 
associated with conjugated and unconjugated primary bile acids, and negatively correlated 317 
with secondary bile acids DCA and LCA.  Group 2 consisted of families positively correlated 318 
with ursodeoxycholic acid.  Group 3 consisted of families positively correlated with secondary 319 
bile acids DCA and LCA, and negatively associated with unconjugated primary bile acids CA 320 
and CDCA.  Enterobacteriaceae, which increased in the recurrent antibiotics group, clustered 321 
in group 1.  Bacteroidaceae, Lachnospiraceae, Ruminococcaceae, and Oscillospiraceae, which 322 
decreased in the recurrent antibiotics group, clustered in group 3. 323 
 324 
3.5. Abundance and activity of bile-metabolising enzymes: 325 
Results from qPCR assays are displayed in Figure 5.  Recurrent antibiotic use was associated 326 
with a significantly reduced abundance of bsh genes for all BSH groups tested compared to 327 
healthy control participants.  Specifically, after recurrent antibiotic use, there was reduced 328 
abundance of the genes of bsh group 1a gene (p < 0.01, Mann-Whitney U test), bsh group 1b 329 
gene (p < 0.05, Mann-Whitney U test), and bsh group 3c/e gene (p < 0.01, Mann-Whitney U 330 
test).  baiCD gene abundance also significantly reduced after recurrent antibiotic use (p < 0.05, 331 
Mann-Whitney U test).   332 
 333 
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Use of recurrent antibiotics is associated with marked reduction in BSH enzyme activity within 334 
faecal samples (Figure 6, p < 0.01, Mann-Whitney U test).   335 
 336 
4. Discussion and Conclusions: 337 
In this study, we performed a range of analyses upon stool samples taken from healthy 338 
participants and people with recent antibiotic use as a means of demonstrating a range of 339 
techniques that may be applied to delineate gut microbiota-host bile acid interactions.   340 
 341 
We found that patients taking recurrent antibiotics had gut microbiotas with reduced 342 
proportions of known bile-metabolising enzyme function, including the families 343 
Bacteroidaceae, Lachnospiraceae and Ruminococcaceae.  Consistent with this, recurrent 344 
antibiotic use was associated with enrichment of stool primary bile acids (both conjugated 345 
and unconjugated) and loss of secondary bile acids.  Correlation analysis showed a distinct 346 
clustering of bacterial families and bile acids into three groups, where Enterobacteriaceae was 347 
positively correlated with unconjugated primary bile acids, and Bacteroidaceae, 348 
Lachnospiraceae, Ruminococcaeceae and Oscillospiraceae were positively correlated with 349 
secondary bile acids.  Further analysis demonstrated a loss of BSH gene abundance and 350 
enzyme activity within the gut of antibiotic-treated patients, coupled with a loss of 7--351 
dehydroxylase baiCD gene abundance related to antibiotic use.  Most fundamentally, these 352 
results emphasise the close and complex interplay between the gut microbiota and bile acid 353 
metabolism, and reinforce that any perturbation of the gut microbiota (in this case by 354 
antibiotics) may result in marked changes to host physiology.  These findings are consistent 355 
with other comparable work within this area, including the demonstration that early life 356 
antibiotic exposure is associated with a long lasting reduction in bile salt hydrolase function 357 
[24].  Furthermore, it has also been recognised that Clostridium difficile infection (a 358 
gastrointestinal infection occurring predominantly in patients with antibiotic-associated gut 359 
dysbiosis) is associated with perturbation of host bile acid profiles, possibly mediated through 360 
alteration of gut bile metabolising enzyme functionality [25]–[27].   361 
 362 
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We used 16S rRNA gene sequencing to determine the differences in the composition of the 363 
gut microbiota between patients taking recurrent antibiotics and healthy controls.  We found 364 
an increase in the relative abundance of Enterobacteriaceae and a decrease in the relative 365 
abundance of Bacteroidaceae, Lachnospiraceae, Ruminococcaceae, and Oscillospiraceae in 366 
the recurrent antibiotic group compared to healthy controls. However, it is important to note 367 
that we are reporting changes in the relative abundances of these groups, not the absolute 368 
abundances.  The total read numbers per sample does not provide information on the total 369 
number of 16S rRNA gene copies in the sample [28].  This is especially important in samples 370 
where a change in the total bacterial biomass occurs, for example with antibiotic treatment 371 
(as is the case in this study).  While it is possible that the absolute abundance of 372 
Enterobacteriaceae increases after recurrent antibiotics, it is also possible that the absolute 373 
abundance of Enterobacteriaceae has remained unchanged, and there was a decrease in the 374 
total biomass due to a decrease in the absolute abundances of Bacteroidaceae, 375 
Lachnospiraceae, Ruminococcaceae, and Oscillospiraceae.  Studies can account for these 376 
changes in bacterial biomass by performing 16S rRNA gene qPCR, and weighting their relative 377 
abundance data to get a more informative representation of the microbial community 378 
composition. 379 
 380 
Whilst 16S rRNA gene sequencing data provides information on the bacterial composition of 381 
the sample, it does not provide information regarding the potential functional capabilities of 382 
the bacteria and subsequent interactions with the host.  Metagenomic sequencing provides 383 
information on the collection of genomes in a sample, followed by assembly or mapping to a 384 
reference database which allows gene annotation.  However, metagenomic sequencing is 385 
more expensive than metataxonomics, and the data analysis can be more challenging.  In this 386 
study, we used Piphillin [12] to indirectly infer the abundance of functional genes as a 387 
straightforward and cost-free addition to the study.  Piphillin has certain advantages 388 
compared to other inferential software tools (including its ease of use, speed of output and 389 
the ability to select a reference database of interest [12]), but has not to our knowledge been 390 
applied before now for analysis of human gut metataxonomic data.  Our intention was to use 391 
this method as an exploratory technique, to later confirm with additional methods of analysis 392 
(qPCR, LC-MS, and an enzyme assay).  The Piphillin results here predicted a reduced bsh gene 393 
abundance in the recurrent antibiotic group compared to healthy controls, and our qPCR data 394 
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and enzyme assay were consistent with this.  Whilst Piphillin predicted a trend towards 395 
reduced secondary bile acid biosynthesis within the recurrent antibiotic group, it was not able 396 
to specifically predict baiCD gene abundance, and we used qPCR to explore this instead.  Our 397 
experience here and in other work with inferential algorithms is that whilst they may be a 398 
helpful and broadly accurate additional tool to start exploring the function of the microbiota, 399 
the current limitations in metagenomic annotation mean that results obtained in this way 400 
must be interpreted with caution.  However, the constant improvements in metagenome 401 
annotation are likely to make such tools ever-more accurate over time.     402 
 403 
Mass spectrometric techniques are the workhorse of bile acids analysis due to their sensitivity 404 
and specificity compared to other assays. High resolution time-of-flight mass spectrometry 405 
using a soft ionization method (electrospray ionization, ESI) coupled with ultra-performance 406 
liquid chromatography is our analytical method of choice as it can provide comprehensive 407 
coverage of bile acids and lipids species from complex biological samples needing minimal 408 
sample pre-treatment [15].  In our study, we found that antibiotic exposure had a significant 409 
impact upon the composition of the bile acid pool, which could have implications on host 410 
physiology.  In order to develop interventions that target the bile acid metabolic pathway, 411 
researchers need to be able to identify specific bacterial taxa responsible for these bile acid 412 
conversions.     413 
 414 
OŶe diffiĐulty ǁith ͚oŵiĐs’ ŵethodologies is the Đoŵpleǆity of the datasets geŶerated, ofteŶ 415 
with very large numbers of variables.  Software packages such as mixOmics offer researchers 416 
useful exploratory approaches to highlight important correlations between bacteria and 417 
metabolites. Integration of metataxonomic and metabonomic data can provide researchers 418 
with information on the potential roles of microorganisms with in an ecosystem, however it 419 
is important to remember that correlation does not equal causation. Strong correlations 420 
between bacteria and metabolites must be confirmed with further experiments, such as 421 
assays in vitro where researchers can assess the direct effects of a substrate/metabolite on 422 
the growth or activity of a microorganisms of interest. Examples of assays in vitro which may 423 
be used include batch cultures, mammalian cell line assays, enzyme assays, etc. It is also 424 
important to note that there is no consensus on which data integration method is the best 425 
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method to integrate metataxonomic and metabonomic data sets, as this is an actively 426 
developing field of research. 427 
 428 
bsh qPCR primer sets were designed to quantify the differences in bsh gene abundance in our 429 
samples.  We found a statistically significant decrease in bsh group 1a, group 1b, and group 430 
G3c/e gene abundance, together with a significant reduction in that of baiCD, associated with 431 
antibiotic use.  Even though these primers were optimised by us to target a select group of 432 
BSH-producing bacteria and were confirmed to not cross-react between groups, the bacterial 433 
strains used from each group during the optimisation stage were subject to availability. 434 
Therefore, it is reasonable to suggest that, due to their degenerate nature, the primers could 435 
also target the bsh gene in other bacterial species within a group which were not tested during 436 
the optimisation stage, thereby potentially providing a more comprehensive assessment of 437 
bsh gene abundance within the faecal samples. DNA sequencing would be required to 438 
categorically confirm the BSH-producing bacterial species targeted by these primer sets.  We 439 
also performed qPCR of the baiCD operon; whilst this operon is not found in all bacteria with 440 
7--dehydroxylating ability, it is present within the two bacterial species with high activity of 441 
this enzyme, Clostridium scindens and Clostridium hiranonis, and most strains of these species 442 
will be amplified by this PCR [19].  Furthermore, Clostridium scindens is particularly of interest 443 
within this context, since its loss from the gut microbiota in association with antibiotic use has 444 
been associated with altered gut bile acid metabolism and a potential vulnerability to 445 
Clostridium difficile infection [27].  Whilst this qPCR will not amplify certain bacteria with low 446 
secondary bile acid biosynthesis functionality (including Clostridium leptum and Clostridium 447 
sordeii), good correlation has been noted between baiCD PCR assay results and 7--448 
dehydroxylase activity in an in vitro assay, demonstrating that this is still a highly useful assay 449 
[19]. 450 
 451 
Whilst qPCR of bacterial genes is useful, similar to metataxonomic data, there are concerns 452 
that what is being assessed relates to which bacterial genes are present, rather than if those 453 
genes are being actively transcribed and the resultant functional effects.  As such, 454 
metatranscriptomics – the sequencing of RNA from within a microbial community – is of great 455 
interest for its ability to more directly establish gene transcription and therefore microbiota 456 
functionality.  However, there remain certain practical difficulties in undertaking such studies, 457 
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including the considerable cost, the computational complexity, and the difficulties in high-458 
quality RNA extraction and sequencing given its relative instability compared to DNA.  459 
Furthermore, whilst protocols have been described that aim to simplify collection of stool and 460 
preserve samples for subsequent streamlined combined metagenomic and 461 
metatranscriptomic analysis (e.g. via the addition of ethanol or RNAlater to samples) [29], the 462 
implications of these preservatives upon the quality of the metabolic profile obtained from 463 
the sample remain undefined.   464 
 465 
The quantification of gene abundance using qPCR data, metagenomic data, and Piphillin data 466 
cannot categorically confirm gene expression and functionality in vivo.  Therefore, we 467 
developed an enzyme activity assay to measure the amount of BSH activity in each sample 468 
through substantial adaptation of a plate-based precipitation assay [21].  Other groups have 469 
used a ninhydrin assay to measure BSH activity [23], [30]; however, these studies used pure 470 
bacterial strains, and in our experience, this assay is not sensitive enough to detect BSH 471 
activity within faecal water.  Whilst BSH activity does not require strict anaerobic conditions, 472 
7--dehydroxylation does [33], complicating development of a similar activity assay.  473 
However, an assay applying thin layer chromatography and radiolabelled cholic acid to human 474 
caecal aspirate or stool obtained after enema use to assess 7--dehydroxylase activity has 475 
been described [33], [32].  476 
 477 
In this study, we compared healthy people with patients taking antibiotics, and did not match 478 
the participants for other demographics.  There are a variety of variables that have been 479 
shown to influence the composition and/or functionality of the gut microbiota, which (in 480 
addition to antibiotics/ microbial infections) include diet, age, surgery, stress, BMI, and 481 
pregnancy[34]–[36].  As such, we are unable to say if the differences seen between our groups 482 
related purely to antibiotic use, or if there was a contribution from other factors.  Where 483 
studies compare healthy and diseased groups in attempting to generate novel hypotheses 484 
regarding the contribution of gut microbiota-bile acid interactions to the disease process, 485 
regard for these factors must be taken to ensure that control groups are appropriate.   486 
   487 
Future challenges regarding methodology within this area remain.  The relationship between 488 
the gut microbiota, bile acid metabolism and the host is complex and bidirectional, and 489 
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methodologies that further delineate this relationship are required.  Development of 490 
standardised pipelines for analysing these complex datasets – coupled with more 491 
standardised methods for integration of different data sets – are key immediate challenges.     492 
At present, whilst there is growing sophistication in our ability to define and correlate gut 493 
microbial and bile acid profiles, there is little work (particularly within humans) that has linked 494 
this back to systemic host effects.  Given the growing recognition that bile acids are signalling 495 
molecules with complex systemic effects upon the host, it is clearly of interest and importance 496 
to be able to link microbial and bile acid interplay to host physiological function, in relation to 497 
health and disease.   498 
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 614 
 615 
Figure legends: 616 
Figure 1: Antibiotics alters the gut microbiota composition in patients taking recurrent 617 
antibiotics compared to healthy controls. (A) Nonmetric multidimensional scaling (NMDS) 618 
plot showing the difference in gut microbiota composition of patients taking recurrent 619 
antibiotics and healthy controls (p < 0.01, PERMANOVA). (B) α diversity was decreased in 620 
patients taking recurrent antibiotics compared to healthy controls (*** p < 0.001, 621 
independent t-test). (C) Richness (total number of bacterial taxa observed) was decreased in 622 
patients taking recurrent antibiotics compared to healthy controls (** p < 0.01, Mann-623 
Whitney U test). (D) Extended error bar plot comparing the differences in the mean 624 
proportions of significantly altered families and the difference in the proportions of the means 625 
;White’s ŶoŶ-parametric t-test with Benjamini-Hochberg FDR). Plot only shows families where 626 
the difference between the proportions was greater than 1%. 627 
 628 
Figure 2:  Inference of bile-metabolising function from 16S data using Piphillin.  (A) Bile salt 629 
hydrolase KEGG orthologue counts (K01442) (* p < 0.05, Mann-Whitney U test). (B) Secondary 630 
bile acid biosynthesis KEGG orthologue counts (ko00121) (p > 0.05, Mann-Whitney U test).   631 
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 632 
Figure 3:  Multivariate analysis of UPLC-MS bile acid profiling data. (A) PCA scores plot (B) 633 
OPLS-DA scores plot (C) OPLS-DA S-plot, showing the contribution of bile acids to the 634 
separation of the two groups.  AB:  recurrent antibiotic treated patients; HC:  healthy controls; 635 
QC: quality controls.   636 
 637 
Figure 4:  Regularized CCA (rCCA) modelling of metataxonomic (16S rRNA gene sequencing 638 
data, family-level) and metabonomic data (bile acid data). (A) The representation of units for 639 
the first two canonical variates showing the correlations between variables in patients 640 
receiving recurrent antibiotics and healthy controls. (B) Correlation circle plot showing strong 641 
correlations between metataxonomic and metabonomic data (plot only shows variables with 642 
a correlation above 0.5). Variables projected in the same direction from the origin have a 643 
strong positive correlation, and variables projected in opposite directions form the origin have 644 
strong negative correlations. Variables that are at a farther distance from the origin have a 645 
stronger correlation. (C) Heatmaps of the rCCA similarity scores between metataxonomic and 646 
metabolomic data. Bacterial families outlined in black boxes clustered according to 647 
correlations with distinct groups of bile acids.  648 
 649 
Figure 5:  qPCR to quantify gene abundance of bile metabolising genes.  (A) bsh group 1a gene 650 
(** p < 0.01, Mann-Whitney U test); (B) bsh group 1b gene (* p < 0.05, Mann-Whitney U test); 651 
(C) bsh group 3c/e (** p < 0.01, Mann-Whitney U test); (D) baiCD gene (p < 0.05, Mann-652 
Whitney U test).   653 
 654 
Figure 6:  Bile salt hydrolase (BSH) enzyme activity assay.  Taurodeoxycholic acid was used as 655 
the substrate for the enzyme assay, and results are therefore expressed as rate of deoxycholic 656 
acid formation (* p < 0.05, Mann-Whitney U test).     657 
Tables: 658 
 659 
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Table 1. Primers used for 16S rRNA gene sequencing on the Illumina MiSeq. The forward 660 
primer mix was composed of four different forward primers, mixed at a ratio of 4:1:1:1 (28F-661 
YM:28F-Borrellia:28FChloroflex:28F-Bifdo). Bases in bold are the MiSeq adapter sequences. 662 
Primer name Primer sequence 
28F-YM 
(forward 
primer) 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAGTTTGATYMTGGCTCAG 
28F-Borrellia 
(forward 
primer) 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAGTTTGATCCTGGCTTAG 
28FChlorofle
x (forward 
primer) 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAATTTGATCTTGGTTCAG 
28F-Bifdo 
(forward 
primer) 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGGTTCGATTCTGGCTCAG 
388R 
(reverse 
primer) 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGCTGCCTCCCGTAGGAG
T 
 663 
 664 
 665 
 666 
 667 
 668 
 669 
 670 
 671 
 672 
 673 
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Table 2. Primers sequence and PCR conditions for bsh and baiCD qPCR. 674 
 675 
 676 
 677 
 678 
 679 
 680 
 681 
 682 
 683 
 684 
 685 
 686 
 687 
 688 
 689 
 690 
 691 
 692 
 693 
 694 
 695 
Group Pƌiŵeƌ SeƋueŶce ;5’-3’Ϳ F/R Cycling 
Conditions 
Expected 
Product 
Size (bp) 
1a 
CACATATTGTGGCACGAACAATH
GAR TGGGG 
F 
95C for 10 
min, (95C 
for 15 sec, 
55C for 1 
min) x 40 
cycles 
570 
CTGTGCCCGGATACAGATTAACR
TAR TTRTT 
 
R 
1b 
CGGCGTTCCGCATTTYTAYGARA
A 
 
F 
95C for 10 
min, (95C 
for 15 sec, 
55C for 1 
min) x 40 
cycles 
318 
GTTCAATGCCAATCGGAATATCR
AAR TTRTT 
 
R 
3c/e 
TTTTGGCCGAACACTGGAYTAYG
ARTT 
 
F 
95C for 5 
min, (95C 
for 15 sec, 
54C for 30 
sec, 72 for 
10 min) x 40 
cycles 
774 
TCAACGGAGCCCAGAATATGRA
ARA AYTG 
 
R 
baiCD 
GGWTTCAGCCCRCAGATGTTCTT
TG 
 
F 
94C for 2 
min, (94C 
for 20 sec, 
52C for 30 
sec, 69C 
for 90 sec) x 
35 cycles, 
68C for 10 
min 
1300 
GAATTCCGGGTTCATGAACATT
CTKCKAAG 
 
R 
Supplementary Material: 
Supplementary Methods: Isolation of bacteria used as standards for bsh gene qPCR: 
Bacteroides plebius, Bacteroides ovatus, and Blautia obeum were previously isolated from the 
stool of a healthy 29 year-old male donor. Bacteroides plebius was isolated from Fastidious 
Anaerobe Agar plates (Acumedia, USA) with 5% horse blood (VWR, USA), Bacteroides ovatus 
was isolated from nutrient agar plates (Sigma-Aldrich, USA), and Blautia obeum was isolated 
from de Man, Rogosa and Sharpe agar plates (Sigma-Aldrich). 
 
DNA extraction was performed on the isolates using the EZNA Isolation Kit Bacterial DNA 
(Omega, USA) with the addition of a bead beating using the Bullet Blender Storm (speed 8 for 
3 min). A ~900 bp region of the 16S gene was amplified using previously published primers 
[1] and DNA was sequenced at Macrogen Europe and isolates were identified by performing 
a standard nucleotide BLAST of the 16S rRNA sequences (NCBI). 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Figure 1:  Bile salt hydrolase grouping map. 
 
 Supplementary Figure 2:  Univariate analysis of differences in specific bile acids between 
healthy participants and people treated with recurrent antibiotics.  (A) Taurocholic acid (* p 
< 0.05, Mann-Whitney U test); (B) Glycocholic acid (* p < 0.05); (C) Cholic acid (** p < 0.01); 
(D) Taurochenodeoxycholic acid (** p < 0.01); (E) Glycochenodeoxycholic acid (* p < 0.05); (F) 
Chenodeoxycholic acid (** p < 0.01); (G) Deoxycholic acid (** p < 0.01); (H) Lithocholic acid 
(** p < 0.01). 
 
 
 
 
 
 Patient characteristics Value 
Sex Male (n= 2), female (n= 3) 
Age 63+/- 14 years 
Prior antibiotics 
Penicillins (n=3), cephalosporins (n=1), 
fluoroquinolones (n=2) 
Significant co-morbidities 
Benign prostatic hypertrophy (n=1), 
diverticulitis (n=1), urinary tract 
infection (n=1), inguinal hernia repair 
within past three months (n=1), 
suspected lung carcinoma (n=1) 
Supplementary Table 1:  Key clinical characteristics of patients included within study.   
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